about
Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris.Enhancing the Protective Immune Response against BotulismRecombinant Alpha, Beta, and Epsilon Toxins of Clostridium perfringens: Production Strategies and Applications as Veterinary VaccinesStability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solutionEvaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry.Selection and characterization of a human monoclonal neutralizing antibody for Clostridium Botulinum neurotoxin serotype BAdenovirus F protein as a delivery vehicle for botulinum BCharacterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening.Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.Small-molecule quinolinol inhibitor identified provides protection against BoNT/A in mice.Botulinum toxin: bioweapon & magic drugEvidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine.Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component.Characterization and immunological activity of different forms of recombinant secreted Hc of botulinum neurotoxin serotype B products expressed in yeast.Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.Vaccines for Category A bioterrorism diseases.Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges.Subunit vaccine efficacy against Botulinum neurotoxin subtypes.Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal routeProtective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.Recombinant holotoxoid vaccine against botulism.Subunit vaccine against the seven serotypes of botulismMucosal vaccine development for botulinum intoxication.Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities.Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticlesLocalization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin.Antibody protection against botulinum neurotoxin intoxication in mice.Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.Botulism, where are we now?Age of Bioterrorism: Are You Prepared? Review of Bioweapons and Their Clinical Presentation for Otolaryngologists.Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies.
P2860
Q25257023-EC7D2FBC-BBAB-4C12-8E7D-4B4F64DECC46Q27678122-00B3EB96-A38D-48CC-91D4-DD29FD2F899FQ28067124-8D7500B9-34AD-4DFF-855F-DB5C5F808B84Q30371202-5AB3AA9B-6D0C-4153-AA3B-88A15D9B4F6BQ33368131-26FD7B0A-C7BF-40BB-904D-9CD86533C527Q33396168-5DF5D6B9-C34F-40DF-B68E-B142C1E1149BQ33627014-8DA8D147-287B-45B7-AEA3-C21F1F6C5D2DQ34033221-F5CB4C54-B532-4073-AE06-68FCF5B2402CQ34038244-27480D17-DA95-44B6-AFD2-A28F5AB2B8F5Q34068107-35364329-2704-4716-92FF-F83259218EB4Q34150431-3CA0EC96-CE7B-4EEF-97DC-995542779F3FQ34291021-E6D0D4A9-66C2-45C2-A21F-2136F362D19AQ34447906-850DC87F-FA58-4354-859F-B9B6EF2DB784Q34530009-1456DDB7-2463-48D0-A79E-0E87077778ECQ34702285-8F8457D0-37F4-486A-96EA-691275B9D1AFQ34713991-E8BC594B-97AE-4EBB-98F9-DF59D4351B28Q34865019-131590F2-EB98-4CD9-B6CD-EF7FFF99D979Q34920929-36009844-3AB4-49EF-A3F1-037DEB3116BBQ35040844-0A4560D6-5460-4290-81DC-2582391EEAB7Q35043107-9C40D39B-7D5E-4893-86C8-7BA229F3162BQ35418294-8F848C8C-6D9A-4021-B5FE-9A23A596DA62Q35532054-7122D325-9126-4BF4-BCA3-78B77F0477ACQ35542237-99F03441-43ED-49D2-A4C5-6D680A0CE066Q35669634-BC1ED7C1-9E09-40C3-A834-8EFC1B4AC727Q35722157-088824A3-D761-46CC-8EEA-14911F719196Q35886818-71DE9EBC-740C-4779-A1AE-A534A7F1C362Q35913397-C76611BC-E434-46AB-8210-F600461FD14CQ36143517-069EA94A-C08E-42CC-8C64-29205E055698Q36422119-00A2B7FB-A506-4595-8187-BD5ED5406590Q36483548-F600AA0F-D8FE-4D69-988B-CA06979B1992Q36728788-CDED1EF5-FF8E-4734-9948-DEC56B71FA15Q36994248-0B6FB967-0A3F-4E58-B432-A511B046A1F2Q37128417-3CDDF50A-325A-487D-B3B8-AFEF60FBE72AQ37130982-304925C1-40B2-4BBF-933F-EB28DAD7E57CQ37258719-C6383F05-7615-4976-97E7-B8EAB835B158Q37355925-392B3755-4DD7-473F-B2B2-0CF17FA459E7Q37384713-CCC2127A-DA34-41EB-8A7D-41E3DB5EF455Q37822447-6893B919-0E6C-4D31-B6C6-5896A6B4892DQ38206493-DF03E189-7388-4D32-8A82-A8F1399B686BQ38337915-00864BEC-4189-42FD-A3D5-0F747A2CE38A
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Development of vaccines for prevention of botulism.
@ast
Development of vaccines for prevention of botulism.
@en
Development of vaccines for prevention of botulism.
@nl
type
label
Development of vaccines for prevention of botulism.
@ast
Development of vaccines for prevention of botulism.
@en
Development of vaccines for prevention of botulism.
@nl
prefLabel
Development of vaccines for prevention of botulism.
@ast
Development of vaccines for prevention of botulism.
@en
Development of vaccines for prevention of botulism.
@nl
P1433
P1476
Development of vaccines for prevention of botulism.
@en
P2093
P304
P356
10.1016/S0300-9084(00)01173-1
P577
2000-09-01T00:00:00Z